ResMed gets Red Dots for respiratory products
ResMed (ASX:RMD) has won two plaudits at this year’s Red Dot Product Design Awards.
The company won Red Dot designation for its AirFit P10 nasal pillow mask and for its soon-to-be-launched Astral 150 life support ventilator.
The AirFit P10 is used to treat sleep apnoea in conjunction with a positive airway pressure (PAP) device.
The Astral 150 is designed to allow chronically ill patient to be treated outside of the hospital for various respiratory conditions, including neuromuscular disease and chronic obstructive pulmonary disease.
“The AirFit P10 and Astral 150 are both backed by decades of science and clinical research as we remain focused on three key goals: improving patient quality of life, preventing progression of chronic diseases, and lowering total healthcare costs,” ResMed CEO Mick Farrell said.
ResMed also received a Red Dot award in 2010 for its S9 series of sleep therapy systems.
This year, there were 4815 entries to the awards and 1120 products received the Red Dot designation.
ResMed (ASX:RMD) shares were trading 2.75% higher at $4.85 as of around 12.30 pm on Tuesday.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
